摘要
背景:肾病是糖尿病的一种使人虚弱的并发症,与肾功能衰竭风险增加有关,导致患者的生活质量较差,最终导致死亡。早期干预对于增进肾病患者的健康至关重要。不幸的是,它不是肾损伤的早期标志物,白蛋白尿是糖尿病和高血压患者肾功能衰退的一个众所周知的预测指标。 目的:评估新的和精确的标记物对于预测肾病的早期发作和进展是必要的。即使在出现临床症状(无微量白蛋白尿)之前,找到可预测肾脏损伤的早期标记也很重要。 结果:使用替代标志物如血清肌酸酐预防和治疗肾脏疾病未被证明是已被证明可降低发病率或死亡率的干预措施的更好指标。许多研究已经阐明了肾损伤标记物的重要性。本文介绍了尿标记物如nephrin,Cystatin C,Monocyte chemoattractant protein(MCP-1),中性粒细胞明胶酶相关脂质运载蛋白(NGAL),肾损伤分子-1(KIM-1)和巢蛋白的意义,早期肾功能不全。 结论:虽然药物治疗取得了显着进展,但与肾病有关的发病率和死亡率依然高居不下。除了血清标记物之外,尿标记物可以更好地预测糖尿病患者对肾脏的损伤进展。
关键词: 糖尿病,炎症,肾脏疾病,尿路标记,肾病,肾功能衰竭。
图形摘要
Current Drug Targets
Title:Early Urinary Markers for Diabetic and Other Kidney Diseases
Volume: 19 Issue: 7
关键词: 糖尿病,炎症,肾脏疾病,尿路标记,肾病,肾功能衰竭。
摘要: Background: Nephropathy is a debilitating complication of diabetes associated with increased risk for renal failure, leading to poor quality of life of the affected patients and eventually to mortality. Early intervention is crucial to enhance the well-being of the patients with nephropathy. Albuminuria is a well-known predictor of weak renal outcomes in patients with diabetes and hypertension, unfortunately, it is not an early marker for kidney injury.
Objective: Assessment of new and precise markers is necessary to predict the early onset and progression of nephropathy. It is important to find early markers which could predict kidney injury even before the clinical signs (no microalbuminuria) appear.
Results: Prevention and therapy for kidney diseases using surrogate markers such as serum creatinine have not proven to be better indicators for interventions that have been shown to decrease morbidity or mortality. A number of studies have elucidated the importance of kidney injury markers. This article describes the significance of urinary markers such as nephrin, Cystatin C, Monocyte chemoattractant protein (MCP-1), neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM- 1) and nestin, which are associated with early renal dysfunction.
Conclusion: Although significant advances have been made in medical therapy, the degree of morbidity and mortality associated with kidney diseases remain despondently high. Besides the serum markers, urinary markers may provide a better prediction of progression of the damage to the kidneys in diabetic patients.
Export Options
About this article
Cite this article as:
Early Urinary Markers for Diabetic and Other Kidney Diseases, Current Drug Targets 2018; 19 (7) . https://dx.doi.org/10.2174/1389450119666180319124639
DOI https://dx.doi.org/10.2174/1389450119666180319124639 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Effects of Incretins on Energy Homeostasis: Physiology and Implications for the Treatment of Type 2 Diabetes Mellitus and Obesity
Current Vascular Pharmacology Medical Therapy of Aortic Aneurysms: A Pathophysiology-Based Approach
Current Vascular Pharmacology Teratological Consequences of Nitric Oxide Synthesis Inhibition
Current Pharmaceutical Design Vitamin D Levels Correlate with Metabolic Syndrome Criteria in Algerian Patients: The Ex-vivo Immunomodulatory Effect of α, 25 Dihydroxyvitamin D3
Endocrine, Metabolic & Immune Disorders - Drug Targets Chemistry and Pharmacology of Neglected Helminthic Diseases
Current Medicinal Chemistry Role of Insulin Signaling in the Interaction Between Alzheimer Disease and Diabetes Mellitus: A Missing Link to Therapeutic Potential
Current Aging Science The Fetal Cardiac Function
Current Cardiology Reviews Targeting Cardiac Mast Cells: Pharmacological Modulation of the Local Renin-Angiotensin System
Current Pharmaceutical Design Benefit of SERCA2a Gene Transfer to Vascular Endothelial and Smooth Muscle Cells: A New Aspect in Therapy of Cardiovascular Diseases
Current Vascular Pharmacology Endothelial Dysfunction: Methods of Assessment & Implications for Cardiovascular Diseases
Current Pharmaceutical Design Natriuretic Peptides as the Basis of Peptide Drug Discovery for Cardiovascular Diseases
Current Topics in Medicinal Chemistry Proteasome Modulator 9 and Depression in Type 2 Diabetes
Current Medicinal Chemistry The L-Type Ca2+ Channel as a Therapeutic Target in Heart Disease
Current Medicinal Chemistry Alzheimer’s Disease and the Early Signs of Age-Related Macular Degeneration
Current Alzheimer Research Therapeutic Value of Statins for Vascular Remodeling
Current Vascular Pharmacology Role for Poly(ADP-ribose) Polymerase Activation in Diabetic Nephropathy, Neuropathy and Retinopathy
Current Vascular Pharmacology Endothelial Dysfunction and the Effects of TNF Inhibitors on the Endothelium in Psoriasis and Psoriatic Arthritis: A Systematic Review
Current Pharmaceutical Design Advancement in Obesity Management: Leptin and Adiponectin Patents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Oleic Acid in Olive Oil: From a Metabolic Framework Toward a Clinical Perspective
Current Pharmaceutical Design Re-Wiring the Circuit: Mitochondria as a Pharmacological Target in Liver Disease
Current Medicinal Chemistry